Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mödling – page 14

863 clinical trials in Mödling, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mödling at a glance
863
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

863 trials in Mödling

Open in trial search

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Insel Gruppe AG

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide
  • Sponsor:ONL Therapeutics Inc.

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:ECRI-trials B.V.

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Takeda Development Center Americas Inc.

Study of plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mödling

What the registry says about research in the country

01 Diabetes & Cardiovascular Health

Clinical research focusing on Type 2 Diabetes Mellitus patients, exploring innovative approaches to prevent heart disease. The trials evaluate the effectiveness of intensive treatment using RAS-antagonists and beta-blockers compared to standard therapy.

  • Heart Disease Prevention
  • Diabetes Management
  • Cardiac Event Reduction

Studies utilize specialized biomarkers like NT-proBNP to guide treatment strategies and reduce hospitalization rates.

02 Stroke Prevention Research

Investigating advanced treatments for ischemic stroke prevention, with particular focus on patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-Stroke Care
  • Blood Clot Prevention
  • Antiplatelet Therapy

The research evaluates the efficacy of asundexian, an oral FXIa inhibitor, in combination with standard antiplatelet therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.